MAS1 oncogene

{{Short description|Protein receptor}}

{{infobox protein

| Name = MAS1 oncogene

| caption =

| image =

| width =

| HGNCid = 6899

| Symbol = MAS1

| AltSymbols =

| EntrezGene = 4142

| OMIM = 165180

| RefSeq = NM_002377

| UniProt = P04201

| PDB =

| ECnumber =

| Chromosome = 6

| Arm = q

| Band = 24

| LocusSupplementaryData = -q27

}}

{{infobox protein

| Name = MAS1 oncogene-like

| caption =

| image =

| width =

| HGNCid = 13961

| Symbol = MAS1L

| AltSymbols =

| EntrezGene = 116511

| OMIM = 607235

| RefSeq = NM_052967

| UniProt = P35410

| PDB =

| ECnumber =

| Chromosome = 6

| Arm = p

| Band = 21

| LocusSupplementaryData =

}}

The MAS1 oncogene (MAS receptor) is a G protein-coupled receptor{{cite journal | vauthors = Nunes-Silva A, Rocha GC, Magalhaes DM, Vaz LN, Salviano de Faria MH, Simoes e Silva AC | title = Physical Exercise and ACE2-Angiotensin-(1-7)-Mas Receptor Axis of the Renin Angiotensin System | journal = Protein and Peptide Letters | volume = 24 | issue = 9 | pages = 809–816 | date = November 2017 | pmid = 28758593 | doi = 10.2174/0929866524666170728151401 | publisher = Bentham Science Publishers Ltd. | quote = (2) a counter-regulatory or vasodilator pathway comprising angiotensin-converting enzyme 2 (ACE2), Angiotensin-(1-7) [Ang-(1-7)] and Mas receptor, which is involved in vasodilation, antiproliferation, anti-hypertrophy, cardioprotective and renoprotective actions. }}{{cite journal | vauthors = Young D, Waitches G, Birchmeier C, Fasano O, Wigler M | title = Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains | journal = Cell | volume = 45 | issue = 5 | pages = 711–9 | date = June 1986 | pmid = 3708691 | doi = 10.1016/0092-8674(86)90785-3 | s2cid = 29886272 }} which binds the angiotensin II metabolite angiotensin (1-7).{{cite journal | vauthors = Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T | display-authors = 6 | title = Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 100 | issue = 14 | pages = 8258–63 | date = July 2003 | pmid = 12829792 | pmc = 166216 | doi = 10.1073/pnas.1432869100 | bibcode = 2003PNAS..100.8258S | doi-access = free }}{{cite journal | vauthors = Santos RA, Ferreira AJ | title = Angiotensin-(1-7) and the renin-angiotensin system | journal = Current Opinion in Nephrology and Hypertension | volume = 16 | issue = 2 | pages = 122–8 | date = March 2007 | pmid = 17293687 | doi = 10.1097/MNH.0b013e328031f362 | s2cid = 32812104 }} The MAS1 receptor, when activated by binding angiotensin-(1-7), opposes many of the effects of the angiotensin II receptor. Hence, MAS1 receptor agonists have similar therapeutic effects to angiotensin II receptor antagonists, including lowering of blood pressure.{{cite journal | vauthors = Santos RA, Ferreira AJ | title = Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist | journal = Cardiovascular Drug Reviews | volume = 24 | issue = 3–4 | pages = 239–46 | year = 2006 | pmid = 17214600 | doi = 10.1111/j.1527-3466.2006.00239.x | doi-access = free }}